[CLVS] Clovis Oncology, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 533.24 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 45.35 Change: 0.32 (0.71%)
Ext. hours: Change: 0 (0%)

chart CLVS

Refresh chart

Strongest Trends Summary For CLVS

CLVS is in the medium-term down -32% below S&P in 1 month and up 13% in 5 months. In the long-term down -83% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has three clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; rucaparib, an oral inhibitor of poly polymerase that is being explored in Phase II or III clinical trials for treating ovarian cancer patients, and Phase II clinical trials for treating pancreatic cancer patients; and lucitanib, an oral inhibitor of the tyrosine kinase Phase I/IIa clinical trials for the treatment of breast and lung cancers. The company's drug discovery program includes the discovery of cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. It has license agreements w

Fundamental Ratios
Shares Outstanding38.39 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV2.11 Price/Cash Per Share
Price/Free Cash Flow-4.47 ROA-27.31% ROE-76.19% ROI
Current Ratio7.93 Quick Ratio Long Term Debt/Equity Debt Ratio0.22
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.19 M Cash From Investing Activities-143.03 M Cash From Operating Activities-48.41 M Gross Profit
Net Profit-63.14 M Operating Profit-64.22 M Total Assets704.71 M Total Current Assets441.7 M
Total Current Liabilities55.68 M Total Debt287.5 M Total Liabilities452.12 M Total Revenue
Technical Data
High 52 week62.4 Low 52 week11.63 Last close25.47 Last change0.59%
RSI51.44 Average true range1.1 Beta1.36 Volume1.42 M
Simple moving average 20 days1.51% Simple moving average 50 days12.88% Simple moving average 200 days-19.89%
Performance Data
Performance Week-0.08% Performance Month6.39% Performance Quart46.63% Performance Half-31.22%
Performance Year-57.46% Performance Year-to-date41.82% Volatility daily2.13% Volatility weekly4.76%
Volatility monthly9.75% Volatility yearly33.78% Relative Volume1318.58% Average Volume2.44 M
New High New Low

News

2019-04-18 11:29:03 | Clovis Focuses on Rubraca Label Expansion, Competition Stiff

2019-04-16 10:38:02 | Company News For Apr 16, 2019

2019-04-15 16:37:35 | Clovis Oncology News: CLVS Stock Sinks on Trial for Cancer Treatment

2019-04-15 15:31:09 | Here's Why Clovis Oncology Stock Dropped as Much as 13% Today

2019-04-15 12:36:36 | Analysts, Options Traders Swarm Sinking CLVS Stock

2019-04-15 09:57:01 | Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer

2019-04-12 18:02:00 | Clovis Oncology stock tumbles after company halts bladder-cancer-treatment trial: report

2019-04-12 17:46:39 | Clovis Oncology, Conduent, Edison International and More: Here’s What The Smart Money Thinks of These Market Movers

2019-04-12 17:37:58 | Clovis Oncology halts mid-stage bladder cancer trial, shares drop

2019-04-10 10:14:02 | AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer

2019-04-03 10:22:02 | Clovis Posts Data on Rubraca Study for Pancreatic Cancer

2019-04-02 09:44:01 | Advaxis Up on Positive Early-Stage Immunotherapy Study Data

2019-04-02 08:30:00 | Clovis Oncology Announces Interim Results from Rubraca® rucaparib Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented at AACR 2019

2019-04-01 08:44:12 | Implied Volatility Surging for Clovis CLVS Stock Options

2019-03-28 09:30:01 | Why Is Clovis CLVS Down 21% Since Last Earnings Report?

2019-03-19 08:00:00 | Clovis Oncology Announces Presentations at 2019 AACR Annual Meeting

2019-03-16 12:45:00 | Clovis Oncology to Highlight Rubraca® rucaparib Data from Post-Hoc ARIEL3 Analyses at SGO 2019 Congress

2019-03-12 10:30:33 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.

2019-03-07 14:07:00 | Did Changing Sentiment Drive Clovis Oncology’s Share Price Down A Worrying 66%?

2019-03-06 16:19:00 | Clovis Oncology to Present at the Barclays Global Healthcare Conference

2019-03-06 07:00:00 | New Research Coverage Highlights Clovis Oncology, Welltower, The Ultimate Software Group, Nielsen Holdings Plc, Xencor, and 21Vianet Group — Consolidated Revenues, Company Growth, and Expectations for 2019

2019-03-05 08:07:14 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.

2019-03-04 03:00:00 | Clovis Oncology Announces Availability of Rubraca®? rucaparib Tablets for Women with Relapsed Ovarian Cancer in Germany

2019-02-27 17:43:00 | Here's Why Clovis Oncology Stock Jumped on Wednesday

2019-02-27 08:12:01 | Clovis CLVS Q4 Earnings Lag Estimates, Rubraca Sales Recover

2019-02-27 07:15:12 | AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study

2019-02-27 00:46:11 | Clovis Oncology Inc CLVS Q4 2018 Earnings Conference Call Transcript

2019-02-27 00:29:42 | Edited Transcript of CLVS earnings conference call or presentation 26-Feb-19 1:30pm GMT

2019-02-26 08:00:00 | Clovis Oncology Announces 2018 Operating Results

2019-02-26 06:30:00 | Clovis Oncology, Inc. to Host Earnings Call

2019-02-22 08:00:00 | Clovis Oncology to Present at the 8th Annual SVB Leerink Healthcare Conference

2019-02-21 09:44:02 | The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis

2019-02-20 10:03:03 | Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More

2019-02-20 08:40:01 | Is the Options Market Predicting a Spike in Clovis Oncology CLVS Stock?

2019-02-19 07:00:00 | Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies

2019-02-13 07:30:00 | New Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services — Consolidated Revenues, Company Growth, and Expectations for 2019

2019-02-12 08:00:00 | Clovis Oncology to Announce Fourth Quarter/Fiscal Year 2018 Financial Results and Host Webcast Conference Call on February 26

2019-02-08 08:02:51 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.

2019-01-29 08:06:41 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.

2019-01-28 07:02:12 | Clovis' Rubraca Gets Nod as Maintenance Therapy in Europe

2019-01-24 13:00:06 | What's Behind the Biotech ETF Rally to Start 2019?

2019-01-24 12:28:00 | Clovis Oncology Announces European Commission Authorization of Rubraca®? rucaparib Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer

2019-01-18 06:41:11 | Immunomedics Gets CRL From FDA for Breast Cancer Candidate

2019-01-17 15:50:50 | Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table

2019-01-17 15:50:50 | Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table

2019-01-15 08:04:48 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.

2019-01-12 12:00:00 | 3 Biotech Stocks That Soared This Week: Are They Buys?

2019-01-11 08:48:01 | Implied Volatility Surging for Clovis Oncology CLVS Stock Options

2019-01-10 06:00:00 | Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause

2019-01-09 08:03:24 | See what the IHS Markit Score report has to say about Clovis Oncology Inc.